Real‐life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52‐week multicentre retrospective study—IL PSO (Italian landscape psoriasis)

Abstract

Background: Tildrakizumab is a humanized monoclonal antibody that binds selectively the p19 subunit of interleukin-23. It is approved for treatment of moderatesevere chronic plaque psoriasis.Objectives: We conducted a 52-week retrospective study to assess the effectiveness and safety of tildrakizumab in a real-life setting.Methods: Our retrospective study included 237 consecutive adults with moderateto-severe plaque psoriasis, enrolled in 10 different Italian centres, treated with tildrakizumab up to Week 52. Patient characteristics, comorbidities, previous treatments

Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective Study

“…40 A recently published retrospective, multicenter real-life study, enrolled a total of 237 patients treated with tildrakizumab up to 52 weeks. 41 Authors' results were in line with our study, showing comparable rates of both PASI 90 and PASI 100 at week 52, which were reached by 73.55% and 58.68% of patients, respectively. 41 An interesting data regarded the difference between bio-naïve patients, in which the efficacy of tildrakizumab resulted to be significantly higher than bio-experienced patients.…”

“…41 Authors' results were in line with our study, showing comparable rates of both PASI 90 and PASI 100 at week 52, which were reached by 73.55% and 58.68% of patients, respectively. 41 An interesting data regarded the difference between bio-naïve patients, in which the efficacy of tildrakizumab resulted to be significantly higher than bio-experienced patients. 41 Indeed, although our study found a slightly higher improvement in bionaïve patients, this resulted a not statistically significant difference; this may come from the higher number of patients enrolled in this study (n=237 vs n=42).…”

“…41 In line with our experience, tildrakizumab resulted a generally safe treatment, with no serious AE reported, no discontinuations due to AE, and with nasopharyngitis and upper respiratory infections as the most reported AEs. 41 The results of our study confirmed tildrakizumab as an effective and generally safe treatment option for the management of moderate-to-severe psoriasis. Indeed, we reported a significant reduction in mean PASI during follow-ups, with even higher rates of PASI90 and PASI100 responses than reSURFACE studies, at both week 16 (PASI90: 52.4%, PASI100: 33.3%) and week 28 (PASI90: 76.1%, PASI100: 61.9%), maintaining these responses up to week 52 (PASI90: 73.8%, PASI100: 59.5%).…”

“…41 Indeed, although our study found a slightly higher improvement in bionaïve patients, this resulted a not statistically significant difference; this may come from the higher number of patients enrolled in this study (n=237 vs n=42). 41 In line with our experience, tildrakizumab resulted a generally safe treatment, with no serious AE reported, no discontinuations due to AE, and with nasopharyngitis and upper respiratory infections as the most reported AEs. 41 The results of our study confirmed tildrakizumab as an effective and generally safe treatment option for the management of moderate-to-severe psoriasis.…”

“…41 An interesting data regarded the difference between bio-naïve patients, in which the efficacy of tildrakizumab resulted to be significantly higher than bio-experienced patients. 41 Indeed, although our study found a slightly higher improvement in bionaïve patients, this resulted a not statistically significant difference; this may come from the higher number of patients enrolled in this study (n=237 vs n=42). 41 In line with our experience, tildrakizumab resulted a generally safe treatment, with no serious AE reported, no discontinuations due to AE, and with nasopharyngitis and upper respiratory infections as the most reported AEs.…”